Semaglutide (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once weekly subcutaneously. This gradual titration improves tolerability and is consistent with FDA-approved dosing strategies for weight management. Administer on the same day each week at any time, with or without meals.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to minimize foaming; avoid shaking.
3. Gently swirl or roll the vial until the powder is fully dissolved.
4. Label the vial with the reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use reconstituted solution within 28 days for maximum potency and safety. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in a cool, dry place protected from light; short-term refrigeration at 2 to 8 °C

is acceptable.

• Reconstituted: refrigerate at 2 to 8 °C and do not freeze; use within 28 days.
• Allow vials to reach room temperature before opening to minimize condensation uptake.

Supplies Needed

Plan based on an 8 to 20 week weekly titration protocol.

Peptide Vials (Semaglutide, 10 mg each):

• 8 weeks: ~1 vial (3 mg total used).
• 12 weeks: ~1 vial (7 mg total used).
• 16 weeks: ~2 vials (13.8 mg total used).
• 20 weeks: ~3 vials (23.4 mg total used with maintenance dosing).

Insulin Syringes (U-100):

• Per week: 1 syringe.
• 8 weeks: 8. 12 weeks: 12. 16 weeks: 16. 20 weeks: 20.

Bacteriostatic Water (10 mL bottles):

• Use 3.0 mL per vial. 20 weeks (3 vials): 1 bottle is sufficient.

Alcohol Swabs:

• Per week: 2 swabs. 20 weeks: 40 swabs (1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid

lipohypertrophy.

• Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
• Administer on the same day each week for consistency; if a dose is missed, take it as soon as possible

within 5 days.

• GLP-1 receptor agonists may cause gastrointestinal side effects (nausea, vomiting); gradual dose

escalation helps minimize these.

• The 10 mg vial size is ideal for the initial 12-week escalation phase, requiring only 1 to 2 vials through

week 16.

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing. Clinical trials have demonstrated significant weight loss (mean 10 to 15% body weight reduction) in individuals with obesity when combined with lifestyle interventions. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach.

Benefits & Side Effects

Observations from clinical literature and regulatory approvals.

• Significant weight loss: mean 10 to 15% body weight reduction in clinical trials at 2.4 mg weekly dose

when combined with lifestyle modifications.

• Improved glycemic control: through enhanced glucose-dependent insulin secretion and reduced

glucagon secretion.

• Reduced appetite: via central nervous system GLP-1 receptor activation.
• Cardiovascular benefits: demonstrated in outcome trials, including reduced risk of major adverse

cardiovascular events.

• Convenient dosing: once-weekly schedule improves adherence compared to daily regimens.
• GI effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain; typically mild to

moderate and decreasing with gradual dose escalation.

• Injection-site reactions (redness, swelling, irritation) generally mild and transient.
• Hypoglycemia risk when combined with insulin or sulfonylureas; less common with Semaglutide

monotherapy due to glucose-dependent mechanism.

• Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors

observed in rodent studies (relevance to humans uncertain).

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2 to 1.6 g/kg body weight) to

preserve lean muscle mass.

• Combine resistance training (2 to 3 days per week) and aerobic exercise (150+ minutes per week) to

reinforce metabolic adaptations.

• Prioritize consistent sleep (7 to 9 hours nightly) and effective stress management to support adherence.
• Stay well-hydrated (8 to 10 glasses of water daily), especially if experiencing gastrointestinal side effects.
• Monitor progress through regular weigh-ins, body measurements, photos, and consultation with

healthcare providers.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely.
2. Pinch a fold of skin; insert the needle at a 45 to 90 degree angle into subcutaneous tissue.
3. Do not aspirate when giving a subcutaneous injection.
4. Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle.
5. Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
6. Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection. The abdomen is preferred for most consistent absorption.
7. Dispose of used syringes and needles immediately in a proper FDA-approved sharps container.

References

Source citations for further reading.

1. Once-Weekly Semaglutide for Weight Management: A Clinical Review (PMC).
2. Semaglutide for Weight Loss in Obesity (PubMed).
3. Semaglutide pharmacology, clinical uses, dosing (NCBI StatPearls).
4. Cardiovascular Outcomes with Semaglutide (PubMed).